Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04129749
Other study ID # 19-HPNCL-01
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date November 17, 2019
Est. completion date December 2021

Study information

Verified date July 2021
Source Fondation Lenval
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To date, studies do not study the influence of external disturbing factors on the market. The main hypothesis is that the stopping of walking in paralyzed cerebral patients is mainly due to an increase in the energy cost of walking. The secondary objectives are to study the causes of the increase in the energy cost of walking (modification of muscle coordination / increase of co-activations, loss of strength, etc.). This study will use the GRAIL combining an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment projected on a 180 ° screen


Description:

In most studies, the study of the gait of cerebral palsy patients is done through quantified walking analysis tests, objectively evaluating the kinetic and kinematic parameters, associated with the measurement of respiratory exchanges and heart rate. Nevertheless this very objective evaluation does not really reflect the child's ability to perform the acts of everyday life that he wishes, and in particular, his ability to walk a long time. It therefore appears that patients do not only want to walk better on an objective and analytical level but also aim to walk longer and improve their walking efficiency. To date, studies do not study the influence of external disturbing factors on the market. The main hypothesis is that the stopping of walking in paralyzed cerebral patients is mainly due to an increase in the energy cost of walking. The main objective is to confirm this hypothesis. The secondary objectives are to study the causes of the increase in the energy cost of walking (modification of muscle coordination / increase of co-activations, loss of strength, etc.). For that, the investigators will use a tool that is perfectly adapted: the GRAIL (Real-Time Analysis Interactive Lab). The GRAIL uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment. Throughout the duration of the test, the investigators will quantify the evolution of biomechanical (kinematic, kinetic and EMG) and physiological (gas analysis system) factors during walking. This is a study conducted in a usual evaluation framework: market analysis is commonly indicated for paralyzed children, in order to assess their disability and to propose the best therapy. There was no inherent risk in the proposed study protocol, but possible fatigue is inevitably analyzed, which is not related to inclusion in this study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2021
Est. primary completion date June 2021
Accepts healthy volunteers No
Gender All
Age group 7 Years to 18 Years
Eligibility Inclusion Criteria: - children aged 7 to 18 years (diplegic, hemiparetic or tetraparetic) requiring treatment with botulinum toxin - followed at the Lenval Foundation - walking alone more than 6 minutes - parental information and no disagreement Exclusion Criteria: - Modification of spasticity treatments within 6 months of evaluation: baclofen pump, oral baclofen, retraction surgery (tenotomy, tendon lengthening, arthrodesis ...) - dyskinesia - Cognitive disorders in children that do not allow the use of GRAIL - Contraindication to Botulinum Toxin (myasthenia, hypersensitivity and infections) - Contraindication to physical activity (intercurrent pathology)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Real-Time Analysis Interactive Lab
The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.

Locations

Country Name City State
France Hôpitaux Pédiatriques de Nice CHU-Lenval Nice

Sponsors (1)

Lead Sponsor Collaborator
Fondation Lenval

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measure of energy cost during walk in cerebral palsy patients, by evolution of inter-segmental angle Measure of energy cost during walk in cerebral palsy patients by quantify modification of muscle coordination / increase of co-activations, loss of strength of muscle.
This will be evaluated by the evolution of inter-segmental angles (degrees) during a 6 minutes walking test.
at baseline Day 0
Primary Measure of energy cost during walk in cerebral palsy patients, by evolution of articular force Measure of energy cost during walk in cerebral palsy patients by quantify modification of muscle coordination / increase of co-activations, loss of strength of muscle.
Also evaluated by the evolution of articular force (N/kg) during a 6 minutes walking test.
at baseline Day 0
Primary Measure of energy cost during walk in cerebral palsy patients by evolution of articular moment Measure of energy cost during walk in cerebral palsy patients by quantify modification of muscle coordination / increase of co-activations, loss of strength of muscle.
Also evaluated by the evolution of articular moment (N.m/kg) during a 6 minutes walking test.
at baseline Day 0
Primary Measure of energy cost during walk in cerebral palsy patients by evolution of articular power Measure of energy cost during walk in cerebral palsy patients by quantify modification of muscle coordination / increase of co-activations, loss of strength of muscle.
Also evaluated by the evolution of articular power (W/kg) during a 6 minutes walking test
at baseline Day 0
Secondary quantification of biomechanical factors during walking by evolution of inter-segmental angles Measure of kinematic and kinetic parameters during walk in cerebral palsy patients.
This will be evaluated by the evolution of inter-segmental angles (degrees) during a 6 minutes walking test.
at baseline Day 0
Secondary quantification of biomechanical factors during walking by evolution of articular force Measure of kinematic and kinetic parameters during walk in cerebral palsy patients.
This will be evaluated by the evolution of articular force (N/kg) during a 6 minutes walking test.
at baseline Day 0
Secondary quantification of biomechanical factors during walking by evolution of articular moment Measure of kinematic and kinetic parameters during walk in cerebral palsy patients.
This will be evaluated by the evolution of articular moment (N.m/kg) during a 6 minutes walking test.
at baseline Day 0
Secondary quantification of biomechanical factors during walking by evolution of of articular power Measure of kinematic and kinetic parameters during walk in cerebral palsy patients.
This will be evaluated by the evolution of of articular power (W/kg) during a 6 minutes walking test.
at baseline Day 0
Secondary measure of physiological factors during walking by evolution of oxygen consummation measure of O2 consummation during walk in cerebral palsy patients by a gas system analysis.
This will be evaluated by the evolution of O2 consummation during walk during a 6 minutes walking test.
at baseline Day 0
Secondary measure of physiological factors during walking by evolution of carbon dioxide consummation measure of CO2 consummation during walk in cerebral palsy patients by a gas system analysis.
This will be evaluated by the evolution of CO2 consummation during walk during a 6 minutes walking test..
at baseline Day 0
See also
  Status Clinical Trial Phase
Recruiting NCT05317234 - Genetic Predisposition in Cerebral Palsy N/A
Recruiting NCT05576948 - Natural History of Cerebral Palsy Prospective Study
Completed NCT04119063 - Evaluating Wearable Robotic Assistance on Gait Early Phase 1
Completed NCT03264339 - The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy N/A
Completed NCT05551364 - Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy N/A
Completed NCT03902886 - Independent Walking Onset of Children With Cerebral Palsy
Recruiting NCT05571033 - Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy N/A
Not yet recruiting NCT04081675 - Compliance in Children With Cerebral Palsy Supplied With AFOs
Completed NCT02167022 - Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy N/A
Completed NCT04012125 - The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy N/A
Enrolling by invitation NCT05619211 - Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities Phase 1
Completed NCT04489498 - Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
Completed NCT03677193 - Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy N/A
Recruiting NCT06450158 - Robot-assisted Training in Children With CP N/A
Completed NCT04093180 - Intensive Neurorehabilitation for Cerebral Palsy N/A
Completed NCT02909127 - The Pediatric Eating Assessment Tool
Not yet recruiting NCT06377982 - Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy Phase 1
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Not yet recruiting NCT03183427 - Corpus Callosum Size in Patients With Pineal Cyst N/A
Active, not recruiting NCT03078621 - Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy Phase 1/Phase 2